Top 20 biopharmas’ market cap rises 6% in Q1 2025 amid tariff headwinds
The top 20 biopharmaceutical companies demonstrated a strong start to 2025, despite ongoing uncertainty surrounding the potential impact of President…
Trump Tariffs
-
-
MSD’s Gardasil sales slide further due to China constraints
A steep fall in demand from China drove a 41% decline in MSD Q1 2025 sales of its human papillomavirus…
-
Thermo Fisher counters tariffs with $2bn investment into US manufacturing
Thermo Fisher has outlaid $2bn to expand manufacturing and development in the US, joining the long list of companies directing…
-
Pharma companies in Europe push for US-level drug prices
Pharmaceutical companies in Europe are requesting the EU to adopt drug pricing strategies comparable to the US, as reported by…
-
Roche announces $50bn US investment in pharma and diagnostics
Roche is set to invest $50bn in pharmaceuticals and diagnostics in the US over the next five years to bolster…
-
Big pharma pushes for European policy change as tariffs loom
Pharmaceutical companies are demanding changes in European regulation as looming tariffs implemented by US President Donald Trump "threaten" billions of…
-
Podcast: What’s next for pharma tariffs?
The US government has signalled a major shift in its trade policies in recent weeks, with several announcements detailing plans…
-
Irish pharmaceutical exports to US soar amid tariff concerns
Irish medical and pharmaceutical exports to the US have seen a significant surge, with a year-on-year increase above 450% in…
-
J&J projects $400m tariff hit but raises sales outlook
Johnson & Johnson Innovative Medicine (J&J) addressed the potential impact of pharmaceutical tariffs during its Q1 2025 earnings call, as…
-
Risk of tariff-triggered global recession growing – GlobalData
The risks of both US and global recessions are growing as a result of uncertainty created by the trade tariffs…
